Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On
NYSE Regulation staff determined that the Company is no longer suitable for
listing pursuant to Section 1033(f)(v) of the NYSE American Company Guide due to
the abnormally low trading price of the Company's common stock. The Exchange's
application to the
The Company has a right to an appeal of this determination by the Exchange, provided that the Company files a written request for such review within seven calendar days after receiving the notice. The Company's Board of Directors is currently considering whether to appeal the Exchange's determination to commence delisting proceedings.
Prior to receipt of the letter from NYSE American, the Company began actively
taking steps to regain compliance with the listing standards of the NYSE
American. Specifically, the Company's Board of Directors unanimously approved
and recommended that the Company's stockholders approve an amendment to the
Company's certificate of incorporation to effect a reverse stock split of the
Company's common stock at a ratio of not less than 5-to-1 and not greater than
15-to-1, with the exact ratio to be determined by the Board in its discretion
before
In the meantime, the Company's common stock will trade on the OTC Pink under the symbol "AMPE". The Company can provide no assurance that its common stock will continue to trade on this market, that brokers will continue to provide public quotes of the Company's common stock on this market or otherwise make a market in the Company's common stock or that the trading volume of the Company's common stock will be sufficient to provide for an efficient trading market.
A copy of the Company's press release dated
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description 99.1 Press Release ofAmpio Pharmaceuticals, Inc. datedOctober 4, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source